Merck Sharp & Dohme (New Zealand) Limited Level 3 123 Carlton Gore Road Newmarket, Auckland 1023 PO Box 99851 Newmarket Auckland 1149 T 09 523-6000 F 09 523-6001 msd.co.nz

23 February 2023



## Lagevrio<sup>®</sup> molnupiravir 200 mg Capsules Extension to Shelf Life of Stock in Market

Dear Healthcare Professional,

Merck Sharp & Dohme (New Zealand) Limited (MSD) writes to inform you that on 21 December 2022 an extension in shelf life for Lagevrio was approved in New Zealand by Medsafe.

The shelf life of Lagevrio has been extended to 30 months. The storage conditions of 'Store below 30°C' remain unchanged. Lagevrio stock currently available in the New Zealand market is labelled with an expiry date of 18 months from the date of manufacture.

This 12-month extension may be applied retrospectively to Lagevrio product manufactured prior to this approval. Cartons and bottles with a labelled expiry date of January 2023 through to May 2023 may remain in use for 12 months beyond the labelled date, as long as the approved storage conditions have been maintained. New expiry dates are shown below.

Batch Number	Printed Expiry Date on Bottles and Cartons	New Expiry Date
CKFXH	January 2023	January 2024
CKFXK	January 2023	January 2024
CKGHZ	March 2023	March 2024
CKGKB	May 2023	May 2024

Please keep this letter with the stock as a reminder of the extended expiry dates.

## Guidance for Pharmacists and Dispensary Team

- Please inform your dispensary team and patients of the new expiry dates.
- The 'Dear Patient' letter which explains the basis for the extension can be provided if you feel the patient requires it.
- Should they have any queries or require any further information, please ask them to contact MSD on 0800 500 673 or via email to DPOC.australia@msd.com

## PLEASE REVIEW THE CURRENT NEW ZEALAND DATA SHEET BEFORE PRESCRIBING OR DISPENSING.

The New Zealand Data Sheet and Consumer Medicines Information can be accessed via the Medsafe website Product/Application Search page: <a href="https://www.medsafe.govt.nz/regulatory/dbsearch.asp">https://www.medsafe.govt.nz/regulatory/dbsearch.asp</a>

## Adverse Event Reporting

Any adverse events which are experienced with Lagevrio can be reported to MSD on 0800 500 673 or via email to <u>DPOC.australia@msd.com</u>.

Yours sincerely,

Dr Gary Jankelowitz

Gary Jankelowitz

Australia and New Zealand Medical Director

T: (02) 8988 8246 M: 0414 795 284

Email: gary.jankelowitz@msd.com